Literature DB >> 24849547

The microbiological diagnosis of tuberculous meningitis: results of Haydarpasa-1 study.

H Erdem1, D Ozturk-Engin, N Elaldi, S Gulsun, G Sengoz, A Crisan, I S Johansen, A Inan, M Nechifor, A Al-Mahdawi, R Civljak, M Ozguler, B Savic, N Ceran, B Cacopardo, A S Inal, M Namiduru, S Dayan, U Kayabas, E Parlak, A Khalifa, E Kursun, O R Sipahi, M Yemisen, A Akbulut, M Bitirgen, O Dulovic, B Kandemir, C Luca, M Parlak, J P Stahl, F Pehlivanoglu, S Simeon, A Ulu-Kilic, K Yasar, G Yilmaz, E Yilmaz, B Beovic, M Catroux, B Lakatos, M Sunbul, O Oncul, S Alabay, E Sahin-Horasan, S Kose, G Shehata, K Andre, A Alp, G Cosić, H Cem Gul, A Karakas, S Chadapaud, Y Hansmann, A Harxhi, V Kirova, I Masse-Chabredier, S Oncu, A Sener, R Tekin, O Deveci, O Karabay, C Agalar.   

Abstract

We aimed to provide data on the diagnosis of tuberculous meningitis (TBM) in this largest case series ever reported. The Haydarpasa-1 study involved patients with microbiologically confirmed TBM in Albania, Croatia, Denmark, Egypt, France, Hungary, Iraq, Italy, Macedonia, Romania, Serbia, Slovenia, Syria and Turkey between 2000 and 2012. A positive culture, PCR or Ehrlich-Ziehl-Neelsen staining (EZNs) from the cerebrospinal fluid (CSF) was mandatory for inclusion of meningitis patients. A total of 506 TBM patients were included. The sensitivities of the tests were as follows: interferon-γ release assay (Quantiferon TB gold in tube) 90.2%, automated culture systems (ACS) 81.8%, Löwenstein Jensen medium (L-J) 72.7%, adenosine deaminase (ADA) 29.9% and EZNs 27.3%. CSF-ACS was superior to CSF L-J culture and CSF-PCR (p <0.05 for both). Accordingly, CSF L-J culture was superior to CSF-PCR (p <0.05). Combination of L-J and ACS was superior to using these tests alone (p <0.05). There were poor and inverse agreements between EZNs and L-J culture (κ = -0.189); ACS and L-J culture (κ = -0.172) (p <0.05 for both). Fair and inverse agreement was detected for CSF-ADA and CSF-PCR (κ = -0.299, p <0.05). Diagnostic accuracy of TBM was increased when both ACS and L-J cultures were used together. Non-culture tests contributed to TBM diagnosis to a degree. However, due to the delays in the diagnosis with any of the cultures, combined use of non-culture tests appears to contribute early diagnosis. Hence, the diagnostic approach to TBM should be individualized according to the technical capacities of medical institutions particularly in those with poor resources.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  PCR; culture; diagnosis; meningitis; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24849547     DOI: 10.1111/1469-0691.12478

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  16 in total

1.  Characteristics and biomarkers of patients with central nervous system infection admitted to a referral hospital in Northern Vietnam.

Authors:  Cuong Chi Ngo; Shungo Katoh; Futoshi Hasebe; Bhim Gopal Dhoubhadel; Tomoko Hiraoka; Sugihiro Hamaguchi; Anh Thi Kim Le; Anh Thi Hien Nguyen; Anh Duc Dang; Chris Smith; Lay-Myint Yoshida; Cuong Duy Do; Thuy Thi Thanh Pham; Koya Ariyoshi
Journal:  Trop Med Health       Date:  2021-05-21

2.  Hamsi scoring in the prediction of unfavorable outcomes from tuberculous meningitis: results of Haydarpasa-II study.

Authors:  Hakan Erdem; Derya Ozturk-Engin; Hulya Tireli; Gamze Kilicoglu; Sylviane Defres; Serda Gulsun; Gonul Sengoz; Alexandru Crisan; Isik Somuncu Johansen; Asuman Inan; Mihai Nechifor; Akram Al-Mahdawi; Rok Civljak; Muge Ozguler; Branislava Savic; Nurgul Ceran; Bruno Cacopardo; Ayse Seza Inal; Mustafa Namiduru; Saim Dayan; Uner Kayabas; Emine Parlak; Ahmad Khalifa; Ebru Kursun; Oguz Resat Sipahi; Mucahit Yemisen; Ayhan Akbulut; Mehmet Bitirgen; Natasa Popovic; Bahar Kandemir; Catalina Luca; Mehmet Parlak; Jean Paul Stahl; Filiz Pehlivanoglu; Soline Simeon; Aysegul Ulu-Kilic; Kadriye Yasar; Gulden Yilmaz; Emel Yilmaz; Bojana Beovic; Melanie Catroux; Botond Lakatos; Mustafa Sunbul; Oral Oncul; Selma Alabay; Elif Sahin-Horasan; Sukran Kose; Ghaydaa Shehata; Katell Andre; Gorana Dragovac; Hanefi Cem Gul; Ahmet Karakas; Stéphane Chadapaud; Yves Hansmann; Arjan Harxhi; Valerija Kirova; Isabelle Masse-Chabredier; Serkan Oncu; Alper Sener; Recep Tekin; Nazif Elaldi; Ozcan Deveci; Hacer Deniz Ozkaya; Oguz Karabay; Seniha Senbayrak; Canan Agalar; Haluk Vahaboglu
Journal:  J Neurol       Date:  2015-01-30       Impact factor: 4.849

3.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

4.  Rational application of adenosine deaminase activity in cerebrospinal fluid for the diagnosis of tuberculous meningitis.

Authors:  Jorge Parra-Ruiz; V Ramos; C Dueñas; N M Coronado-Álvarez; R Cabo-Magadán; V Portillo-Tuñón; D Vinuesa; L Muñoz-Medina; J Hernández-Quero
Journal:  Infection       Date:  2015-04-14       Impact factor: 3.553

5.  The burden and epidemiology of community-acquired central nervous system infections: a multinational study.

Authors:  H Erdem; A Inan; E Guven; S Hargreaves; L Larsen; G Shehata; E Pernicova; E Khan; L Bastakova; S Namani; A Harxhi; T Roganovic; B Lakatos; S Uysal; O R Sipahi; A Crisan; E Miftode; R Stebel; B Jegorovic; Z Fehér; C Jekkel; N Pandak; A Moravveji; H Yilmaz; A Khalifa; U Musabak; S Yilmaz; A Jouhar; N Oztoprak; X Argemi; M Baldeyrou; G Bellaud; R V Moroti; R Hasbun; L Salazar; R Tekin; A Canestri; L Čalkić; L Praticò; F Yilmaz-Karadag; L Santos; A Pinto; F Kaptan; P Bossi; J Aron; A Duissenova; G Shopayeva; B Utaganov; S Grgic; G Ersoz; A K L Wu; K C Lung; A Bruzsa; L B Radic; H Kahraman; M Momen-Heravi; S Kulzhanova; F Rigo; M Konkayeva; Z Smagulova; T Tang; P Chan; S Ahmetagic; H Porobic-Jahic; F Moradi; S Kaya; Y Cag; A Bohr; C Artuk; I Celik; M Amsilli; H C Gul; A Cascio; M Lanzafame; M Nassar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-10       Impact factor: 3.267

Review 6.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

Review 7.  Tuberculosis Meningitis.

Authors:  Kassem Bourgi; Christina Fiske; Timothy R Sterling
Journal:  Curr Infect Dis Rep       Date:  2017-09-11       Impact factor: 3.725

8.  Clinical features, Outcomes and Molecular Profiles of Drug Resistance in Tuberculous Meningitis in non-HIV Patients.

Authors:  Jingya Zhang; Xuejiao Hu; Xin Hu; Yuanxin Ye; Mengqiao Shang; Yunfei An; Haimei Gou; Zhenzhen Zhao; Wu Peng; Xingbo Song; Yanhong Zhou; Mei Kang; Yi Xie; Xuerong Chen; Xiaojun Lu; Binwu Ying; Lanlan Wang
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

9.  Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study.

Authors:  Seniha Senbayrak; Nuri Ozkutuk; Hakan Erdem; Isik Somuncu Johansen; Rok Civljak; Ayse Seza Inal; Uner Kayabas; Ebru Kursun; Nazif Elaldi; Branislava Savic; Soline Simeon; Emel Yilmaz; Olga Dulovic; Derya Ozturk-Engin; Nurgul Ceran; Botond Lakatos; Oguz Resat Sipahi; Mustafa Sunbul; Mucahit Yemisen; Selma Alabay; Bojana Beovic; Aysegul Ulu-Kilic; Yasemin Cag; Melanie Catroux; Asuman Inan; Gorana Dragovac; Ozcan Deveci; Recep Tekin; Hanefi Cem Gul; Gonul Sengoz; Katell Andre; Arjan Harxhi; Yves Hansmann; Serkan Oncu; Sukran Kose; Oral Oncul; Emine Parlak; Alper Sener; Gulden Yilmaz; Umit Savasci; Haluk Vahaboglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-11-04       Impact factor: 3.944

10.  Pleocytosis in a patient with relapsing polychondritis accompanied by meningoencephalitis: a case report.

Authors:  Jie Cao; Min Zhang
Journal:  BMC Neurol       Date:  2018-04-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.